Get the Stockscreener App
1.04
3.70%
-0.04
After Hours:
1.05
0.01
+0.96%
Allarity Therapeutics Inc Stock (ALLR) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect - Markets Insider
Allarity Therapeutics advances ovarian cancer drug trial - Investing.com
Allarity Therapeutics Announces Expansion of Phase 2 - GlobeNewswire
Breakthrough Ovarian Cancer Drug Shows 14-Month Durability: Allarity Advances Clinical Trial - StockTitan
Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation - Markets Insider
Allarity Therapeutics Inc’s Shares Reel: -24.64% Quarterly Revenue Decline Amid 4.68M Market Cap - The InvestChronicle
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Reach Out - Markets Insider
ALLR’s earnings forecast for the current quarter - US Post News
Ratios Reveal: Breaking Down Allarity Therapeutics Inc (ALLR)’s Financial Health - The Dwinnex
Allarity Therapeutics Reaches Settlement in Principle with SEC - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect - Markets Insider
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC - GlobeNewswire
Allarity's Stenoparib Shows 14-Month Patient Response as Company Nears SEC Resolution - StockTitan
2025-01-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect | NDAQ:ALLR | Press Release - Stockhouse Publishing
ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
No Stopping Allarity Therapeutics Inc (NASDAQ: ALLR)’s Stock Surged? - Stocks Register
2025-01-19 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
2025-01-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out | NDAQ:ALLR | Press Release - Stockhouse Publishing
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
2025-01-08 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation - AccessWire
2025-01-02 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
2024-12-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - The Eastern Progress Online
ALLARITY THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws - The Eastern Progress Online
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - Kilgore News Herald
ALLR Deadline: ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Eastern Progress Online
Allarity Therapeutics stock hits 52-week low at $1.03 - Investing.com
Allarity Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Allarity Therapeutics, Inc. Inc. of Class Action Lawsuit and Upcoming DeadlinesALLR - Longview News-Journal
Allarity Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
Allarity Therapeutics stock hits 52-week low at $1.14 By Investing.com - Investing.com South Africa
Allarity Therapeutics stock hits 52-week low at $1.14 - Investing.com
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):